{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-22-000121","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2022-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.108815+00:00","generated_at":"2026-06-21T04:31:47.281228+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Exelixis announces CSO transition; Peter Lamb steps down; Dana Aftab promoted","bullets":["Peter Lamb transitions from CSO to EVP, Scientific Strategy effective December 15, 2022.","Dana T. Aftab, Ph.D., appointed as new CSO and EVP, Discovery and Translational Research.","Dr. Aftab has over 24 years at Exelixis, most recently EVP, Business Operations.","He previously led discovery and development of cabozantinib and streamlined translational processes."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-22-000121","json":"https://secwatch.observer/filing/0000939767-22-000121.json","markdown":"https://secwatch.observer/filing/0000939767-22-000121.md","text":"https://secwatch.observer/filing/0000939767-22-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/0000939767-22-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/exel-20221215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:31:47.281228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b2d5ef067","claim":"Peter Lamb changed role as Executive Vice President, Scientific Strategy at EXELIXIS, INC..","evidence_excerpt":"Peter Lamb, Ph.D., currently, Executive Vice President, Scientific Strategy and Chief Scientific Officer of Exelixis, Inc. (“Exelixis” or the “Company”), will transition into a new role as Executive Vice President, Scientific Strategy, effective as of today.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/0000939767-22-000121-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Executive Vice President, Scientific Strategy"}],"fact_type":"executive_change"},{"claim_id":"7c39ce0c31","claim":"Dana T. Aftab was appointed as Chief Scientific Officer at EXELIXIS, INC..","evidence_excerpt":"Dana T. Aftab, Ph.D., will become the Company’s next Chief Scientific Officer and will also serve as Executive Vice President, Discovery and Translational Research.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/0000939767-22-000121-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}